Publication | Closed Access
CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 Years
93
Citations
9
References
2008
Year
The immunostimulatory properties of CPG 7909 present an important strategy in achieving long-term protection in HIV-infected patients and other HBV vaccine-hyporesponsive populations.
| Year | Citations | |
|---|---|---|
Page 1
Page 1